Liraglutide for Obstructive Sleep Apnea Improvement

Patient Selection and Treatment

The American Thoracic Society guidelines recommend liraglutide for patients with obstructive sleep apnea, as it has randomized controlled trial evidence demonstrating improvement in OSA outcomes, with a reduction in apnea-hypopnea index (AHI) of 6.1 events/hour more than placebo, and 5.7% weight loss compared to 1.6% with placebo, in patients with moderate to severe OSA (AHI ≥15 events/h) 1, 2, 3
Liraglutide is indicated for patients with a BMI ≥27 kg/m² with OSA as a weight-related comorbidity, or BMI ≥30 kg/m², who have failed comprehensive lifestyle intervention, and have no active cardiovascular disease 1, 2, 3, 5
The American Thoracic Society guidelines identify liraglutide as having direct evidence for OSA improvement, with a dedicated randomized controlled trial specifically enrolling OSA patients and measuring OSA severity as the primary endpoint 1, 2, 3

Liraglutide should be started at 0.6 mg subcutaneously daily and escalated by 0.6 mg weekly until reaching a maintenance dose of 3.0 mg daily, and continued indefinitely to maintain weight loss 4

Patients on liraglutide should be monitored for gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, which are dose-dependent and most common during titration 1, 2, 5, 3
Patients should also be watched for signs of pancreatitis, gallbladder disease, and changes in blood pressure, which may require antihypertensive medication adjustment 5, 4, 6, 5

Phentermine/topiramate ER may be considered as a non-GLP-1 option for patients with OSA, with a demonstrated AHI reduction of 14.9 events/h and 6.5 kg greater weight loss versus placebo, but has cardiovascular safety concerns and should be avoided in patients with active cardiovascular disease 6, 2, 5